Aeglea a clinical-stage biotechnology company that engineers next generation human enzymes with enhanced properties and novel activity to provide solutions for diseases with unmet medical need. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency and in combination with an immune checkpoint inhibitor for small cell lung cancer. Aeglea has two pipeline programs in IND-enabling studies for Homocystinuria and Cystinuria and an active discovery pipeline. Source
No articles found.
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...
Corbus Pharmaceuticals Holdings, Inc. is a Phas...
HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new...
HOOKIPA Pharma Inc. is a clinical stage biophar...
Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnolo...
Mirati Therapeutics (NASDAQ: MRTX) is a San Die...
Cidara is a clinical-stage biotechnology company focused on the discovery, develop...
Cidara is a clinical-stage biotechnology compan...
Join the National Investor Network and get the latest information with your interests in mind.